Perspective and the measurement of costs and benefits for cost- effectiveness analysis in schizophrenia

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 3, 1999, Pages 32-37

  Meltzer, David ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; MENTAL HEALTH CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FAMILY HEALTH; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; SCHIZOPHRENIA;

EID: 0032971325     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
2. Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment, II: economic benefit-cost analysis. Arch Gen Psychiatry 1980;37:400-405
3. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165(suppl 25):18-21
4. Franks DD. Economic contribution of families caring for persons with severe and persistent mental illness. NIMH contract no. 87M020295501D, Division of Biometry and Applied Sciences Research; November 1987. Adm Pol Ment Health 1990; 18
5. Meltzer DO. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
6. Revicki DA, Luce BR, Weschler JM, et al., Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854
7. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42